Normalized Membrane Ratio (NMR) of TROP2 by Quantitative Continuous Scoring is predictive of Clinical Outcomes in TROPION-Lung 01. OncoAlert #WCLC24 ✅Improved ORR and mPFS w/ DatoDxd in NMR+ vs NMR- in all comers & in pts w/ NSq-NSCLC w/o AGA. ❌No association between NMR

Finally, it has been shown that the response to anti-TROP2 ADC is dependent on the expression of the TROP2 target gene. This aligns with the mechanism of action of ADCs, which has been thoroughly validated, particularly for anti-HER2 ADCs, e.g. DAISY Trial or DESTINY-PanTumor02

New article in press: A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases. FabriceAndre G Curigliano MD PhD Nadia Harbeck,MD PhD doi.org/10.1016/j.anno…

Stellar presentation on ADCs targeting TROP-2, MET, and CEACAM by our Dr. Joshua Reuss MET and TROP-2 ADCs have been actively investigated and may potentially become part of SOC. Qs: biomarkers, sequencing approaches if multiple ADCs available, improving therapeutic index

Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com

🔥🚨OncoAlert Hot off the press. Just published NEJM in conjunction with presentation ESMO - Eur. Oncology #ESMO24 Results of #Positive Phase 2 trial of #Ponsegromab (#GDF15 inhibitor) vs #Placebo for treatment of #Cachexia in patients with #Cancer. 👇🏼 nejm.org/doi/full/10.10…

PEACE-3 reinvigorating the role of Radium-223? Improves rPFS and likely OS as first line treatment in mCRPC in combination with enza. Results much more impressive than I expected! silke gillessen #ESMO24 But has landscape already changed with LuPSMA?? Should we consider Ra-223

The paper "Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group" is out aacrjournals.org/clincancerres/…

Critical review of Nectin-4 in EV-302 vs. Literature needed!🧵 The recent findings from the EV-302 trial #ESMO24, demonstrating high Nectin-4 expression in almost all UC (median H-score >250) are in stark contrast with the literature, which were published independently of the

Niklas Klümper I want to see images of the staining, why are they not being disclosed ?

Exited to share the first results from the TOMBOLA trial presented at #ESMO24 by Jørgen Bjerggaard. We used tumor informed (WES; ddPCR) ctDNA analysis to guide Atezolizumab treatment after cystectomy using longitudinally collected blood samples. Key findings: •CtDNA-negative

Interesting efficacy signal for bladder preservation (TMT) + nivolumab. Increased #bladdercancer free survival & OS va TMT No new safety issue. Additional data expected from GETUG Bladder Sparing study. Larger trials needed. #ESMO2024

Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g #ESMO24 | ESMO - Eur. Oncology

The future of biomarkers….GOING SPACIAL #ESMO24 ESMO - Eur. Oncology

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024

Congrats Lars Dyrskjøt !! Great data. ctDNA seems to be great for risk stratification. When do you expect mature survival data for the intervention group ? Next year ?

⭐️It was such a great honor to talk about “Tumor-Agnostic Biomarker Driven Drug development: How & How often?” at the special joint session of ASCO & ESMO - Eur. Oncology meeting #ESMO24 #ESMOAmbassadors ! ⭐️Grateful to our beloved ASCO President Robin Zon, MD, FACP, FASCO & amazing ESMO President

Words of Wisdom Wednesday: Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer by Niklas Klümper, Francisco E. Vera Badillo, Markus Eckstein, Boris Hadaschik and Viktor Grünwald Read the full article here: buff.ly/47kxeS9 #UroSoMe #MedTwitter